New therapeutic aspects: haemopoietic stem cell transplantation

被引:7
作者
Bacon, PA [1 ]
Carruthers, D
机构
[1] Univ Birmingham, Sch Med, Dept Rheumatol, Div Immun & Infect, Birmingham B15 2TT, W Midlands, England
[2] City Hosp NHS Trust, Dept Rheumatol, Birmingham, W Midlands, England
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2001年 / 15卷 / 02期
关键词
vasculitis; stem cell transplantation; high dose immunosuppression; stem cell mobilisation; condition;
D O I
10.1053/berh.2000.0145
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary systemic vasculitis responds well to intensive immunosuppression, particularly with cyclophosphomide. Use of the latter is restricted by side-effects, particularly in relapsing disease. Techniques which allow more complete immunosuppression have an obvious attraction in autoimmune disease. They are particularly suitable for vasculitis which can go into long-lasting remission even with standard therapy in many cases. The conditioning used for stem cell transplantation allows more complete deletion of auto aggressive T-cell clones, with subsequently haemopoietic rescue by previously harvested stem cell precursors. The procedure also has immune potentiating effects, perhaps by promoting peripheral suppressor mechanisms. These may be important even though immune ablation is not achieved. With rigorous patient selection, experience with this technique in vasculitis may be broadened.
引用
收藏
页码:299 / 313
页数:15
相关论文
共 48 条
[1]   Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].
Albert, ML ;
Sauter, B ;
Bhardwaj, N .
NATURE, 1998, 392 (6671) :86-89
[2]  
ANDERSON G, 1992, Q J MED, V83, P427
[3]  
BACON PA, 1999, HORIZONS MED, V11, P123
[4]   Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo [J].
Bhagat, K ;
Vallance, P .
CIRCULATION, 1997, 96 (09) :3042-3047
[5]   The role of T-cell depletion of autografts for autoimmune diseases [J].
Bierings, M .
RHEUMATOLOGY, 1999, 38 (08) :755-756
[6]   Giant cell vasculitis is a T cell-dependent disease [J].
Brack, A ;
Geisler, A ;
MartinezTaboada, VM ;
Younge, BR ;
Goronzy, JJ ;
Weyand, CM .
MOLECULAR MEDICINE, 1997, 3 (08) :530-543
[7]  
BREEDVELD FC, 1996, VASCULITIDES SCI PRA, P39
[8]   Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation [J].
Brodsky, RA ;
Sensenbrenner, LL ;
Jones, RJ .
BLOOD, 1996, 87 (02) :491-494
[9]   Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease [J].
Brodsky, RA ;
Petri, M ;
Smith, BD ;
Seifter, EJ ;
Spivak, JL ;
Styler, M ;
Dang, CV ;
Brodsky, I ;
Jones, RJ .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1031-1035
[10]  
Carruthers DM, 1998, ARTHRITIS RHEUM, V41, pS123